Compare ESQ & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | TBPH |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.4M | 1.0B |
| IPO Year | 2017 | 2013 |
| Metric | ESQ | TBPH |
|---|---|---|
| Price | $100.73 | $13.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $118.00 | $29.20 |
| AVG Volume (30 Days) | 60.3K | ★ 423.6K |
| Earning Date | 04-23-2026 | 06-01-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 4.68 | N/A |
| EPS | ★ 4.32 | 0.88 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $22.47 | $70.90 |
| Revenue Next Year | $10.25 | N/A |
| P/E Ratio | $23.88 | ★ $21.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $69.14 | $7.90 |
| 52 Week High | $119.86 | $21.03 |
| Indicator | ESQ | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.64 | 23.39 |
| Support Level | $99.97 | $13.58 |
| Resistance Level | $106.32 | $14.76 |
| Average True Range (ATR) | 3.98 | 0.97 |
| MACD | -0.90 | -0.41 |
| Stochastic Oscillator | 17.43 | 12.30 |
Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).